3D Systems’ focus on 3D printing within the medical sector is no secret, particularly since it acquired Medical Modeling earlier this year. The company is obviously not content to sit on its laurels as far as the medical field is concerned either — yesterday 3DS announced that it has definitively agreed to acquire Simbionix — for $120 million in cash, with the deal expected to be closed by the end of August. As a global leader in 3D virtual reality surgical simulation, Simbionix is likely to boost 3D Systems’ capabilities in the healthcare field with its 16 simulation platforms for a wide range of medical procedures.
“Simbionix is a perfect match for our healthcare business and its powerful technology, products, channels and domain expertise expands our 3D healthcare capabilities from the training room to the operating room, and extends our first mover advantage in this fast growing vertical,” said Avi Reichental, President and Chief Executive Officer, 3DS.
Headquartered in Cleveland, Ohio with a research and development center in Israel, Simbionix pioneered patient-specific simulation with FDA-cleared solutions that are changing the way preparation for individual surgeries are carried out. Its proprietary simulation and training products are widely contributing to the way physicians practice and master surgical procedures with improved learning that can favorably impact patient outcomes.
“3D Systems is the recognized 3D healthcare leader and they have an exceptional track record of commercially deploying innovative virtual surgery and medical device products and services,” said Gary Zamler, Simbionix Corporation CEO. “We couldn’t be more excited to join this fine organization and look forward to accelerate our growth by enhancing the entire 3D digital thread for the benefit of our customers worldwide.”
In addition to synergistic technology and products, 3DS also sees Simbionix bringing its global sales channels and deep clinical relationships to the 3D printing company which, it is planned, will accelerate the adoption of best medical practices, to advance clinical performance, and to optimize procedural outcomes. 3DS plans to operate Simbionix under the continued leadership of Gary Zamler, CEO of Simbionix, who will become Vice President and General Manager, Simbionix Products for 3DS.